R.S. (Maurice) van den Claasen

R.S. (Maurice) van den Claasen

Full Professor
  • Radiology



Maurice van den Bosch (1974) studied Biomedical Health Sciences (MSc) and Medicine (MD) at the Radboud University Nijmegen, the Netherlands. He finished his PhD thesis within the field of Epidemiology and became a resident in Radiology at the University Medical Center (UMC) Utrecht. He did a two-years postdoctoral fellowship Interventional Radiology at Stanford University Medical Center, USA. In 2009 he obtained a faculty position as Interventional Radiologist in UMC Utrecht. His main interest is development and clinical translation of novel image-guided techniques for treatment of cancer. He co-founded the Center of Interventional Oncology and was appointed on Professor of Radiology at the UMC Utrecht in 2011. From 2013 he joined the management team of the RvE oncology UMC Utrecht (the UMC Utrecht Cancer Center). In 2014 he was appointed Chairman of Radiology and Nuclear Medicine UMC Utrecht. In 2017 he was appointed CEO of the OLVG hospital in Amsterdam, and also joined the Board of the Santeon Hospital Group, a network of seven large top clinical medical centers in the Netherlands, of which he was appointed Chairman in 2019.

Side Activities

Today - 2019:
Board member of SIGRA (Samenwerkende Instellingen Gezondheidszorg Regio Amsterdam). SIGRA is a collaboration of all healthcare and care organizations within Amsterdam and the surrounding townships.
Responsible for the portfolio: ICT and innovation.*
Today - 2016:
Advisory board member Vilans. Vilans is a nationwide knowledge and expertise center for long-term and disabled care organizations. Responsible for the portfolio: Quality and innovation (and vice-chairman). [paid]
Today - 2015:
Member of the Utrecht Medical Fraternity “Matthias van Geuns”, founded in 1793. Chairman in 2016-18.*
2016 - 2012:
Member European School of Radiology Leadership Board.*
2016 - 2010:
Board member CIRSE (Cardiovascular and Interventional Radiological Society of Europe) Advisory Council.*
2014 - 2009:
Chairman Dutch Society of Interventional Radiology, Taskforce Interventional Oncology.*
2013 - 2008:
Member Scientific Board Pink Ribbon. Breast Cancer Research Foundation. Honorary member since 2013.*

*: unpaid

Fellowship and Awards

2019: ZonMw-VWS “Experiment Uitkomstindicatoren” Santeon: 1.2-2.4mln euro.
2014: Research grant Dutch Cancer Foundation: “Saving breast cancer patients from ineffective treatment”: 948.000 euro
2012: Research grant Center for Translational Molecular Medicine (CTMM) “Imaging Guided and Targeted Drug Delivery”: 6.381.000 euro. Project leader: “Application of MRI-guided HIFU to improve cancer chemotherapy with temperature sensitive targeted nanomedicines”.
2010: Clinical Cancer Research Award Dutch Cancer Foundation: “ 588.400 euro. Project: “Holmium-166 radioembolization of liver malignancies”.
2010: Clinical Fellow ZonMw: 160.000 euro. Project: “High intensity focused ultrasound ablation of breast cancer”.
2009: Grant Nuts Ohra research foundation: 244.000 euro. Project: “Quality of life in patients treated with Yttrium-90 radioembolization for liver cancer”.

Research Output (234)

Supplemental Breast MRI for Women with Extremely Dense Breasts:Results of the Second Screening Round of the DENSE Trial

Veenhuizen Stefanie G A, de Lange Stéphanie V, Bakker Marije F, Pijnappel Ruud M, Mann Ritse M, Monninkhof Evelyn M, Emaus Marleen J, de Koekkoek-Doll Petra K, Bisschops Robertus H C, Lobbes Marc B I, de Jong Mathijn D F, Duvivier Katya M, Veltman Jeroen, Karssemeijer Nico, de Koning Harry J, van Diest Paul J, Mali Willem P T M, van den Bosch Maurice A A J, van Gils Carla H, Veldhuis Wouter B, 16 Mar 2021, In: Radiology. 299 , p. 278-286 9 p.

Meerwaarde van MRI-screening bij zeer dicht borstweefsel in het bevolkingsonderzoek borstkanker

de Lange Stéphanie V., Bakker Marije F., Pijnappel Ruud M., Mann Ritse M., Peeters Petra H.M., Monninkhof Evelyn M., Emaus Marleen J., Loo Claudette E., Bisschops Robertus H.C., Lobbes Marc B.I., de Jong Mathijn D.F., Duvivier Katya M., Veltman Jeroen, Karssemeijer Nico, de Koning Harry J., van Diest Paul J., Mali Willem P.T.M., van den Bosch Maurice A.A.J., Veldhuis Wouter B., van Gils Carla H. Apr 2020, In: Nederlands Tijdschrift voor Geneeskunde. 164 10 p.

Supplemental MRI Screening for Women with Extremely Dense Breast Tissue

Bakker Marije F, de Lange Stéphanie V, Pijnappel Ruud M, Mann Ritse M, Peeters Petra H M, Monninkhof Evelyn M, Emaus Marleen J, Loo Claudette E, Bisschops Robertus H C, Lobbes Marc B I, de Jong Matthijn D F, Duvivier Katya M, Veltman Jeroen, Karssemeijer Nico, de Koning Harry J, van Diest Paul J, Mali Willem P T M, van den Bosch Maurice A A J, Veldhuis Wouter B, van Gils Carla H, 28 Nov 2019, In: The New England journal of medicine. 381 , p. 2091-2102 12 p.

Quality of life in patients with liver tumors treated with holmium-166 radioembolization

van Roekel Caren, Smits Maarten L J, Prince Jip F, Bruijnen Rutger C G, van den Bosch Maurice A A J, Lam Marnix G E H 15 Nov 2019, In: Clinical & Experimental Metastasis. 37 , p. 95-105 11 p.

Contradiction between amide-CEST signal and pH in breast cancer explained with metabolic MRI

Krikken Erwin, van der Kemp Wybe J.M., Khlebnikov Vitaliy, van Dalen Thijs, Los Maartje, van Laarhoven Hanneke W.M., Luijten Peter R., van den Bosch Maurice A.A.J., Klomp Dennis W.J., Wijnen Jannie P. 1 Aug 2019, In: NMR in Biomedicine. 32 , p. e4110

MRI guided focal HDR brachytherapy for localized prostate cancer:Toxicity, biochemical outcome and quality of life

Maenhout Metha, Peters Max, Moerland Marinus A, Meijer Richard P, van den Bosch Maurice A A J, Frank Steven J, Nguyen Paul L, van Vulpen Marco, van der Voort van Zyp Jochem R N Dec 2018, In: Radiotherapy & Oncology. 129 , p. 554-560

Accuracy of SPECT/CT based lung dose calculation for Holmium-166 hepatic radioembolization before OSEM convergence

van Nierop B J, Prince J F, van Rooij R, van den Bosch M A A J, Lam M G E H, de Jong H W A M Aug 2018, In: Medical Physics. 45 , p. 3871-3879 9 p.

Additional hepatic <sup>166</sup>Ho-radioembolization in patients with neuroendocrine tumours treated with <sup>177</sup>Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial):a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

Braat Arthur J A T, Kwekkeboom Dik J, Kam Boen L R, Teunissen Jaap J M, de Herder Wouter W, Dreijerink Koen M A, van Rooij Rob, Krijger Gerard C, de Jong Hugo W A M, van den Bosch Maurice A A J, Lam Marnix G E H 15 Jun 2018, In: BMC Gastroenterology [E]. 18 , p. 1-11

Efficacy of radioembolization with holmium-166 microspheres in salvage patients with liver metastases:a phase 2 study

Prince Jip F, van den Bosch Maurice A A J, Nijsen J F W, Smits Maarten L J, van den Hoven Andor F, Nikolakopoulos Stavros, Wessels Frank J, Bruijnen Rutger C G, Braat Manon, Zonnenberg BA, Lam Marnix 1 Apr 2018, In: Journal of Nuclear Medicine. 59 , p. 582-588 7 p.

Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up:A cohort study

Braat Arthur J A T, Prince Jip F, van Rooij Rob, Bruijnen Rutger C G, van den Bosch Maurice A A J, Lam Marnix G E H Mar 2018, In: European Radiology. 28 , p. 920-928

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not